IBD item numbers
PBS item numbers and streamlined authority codes for biologics and small molecules in ulcerative colitis and Crohn's disease. Select a number to copy it.
Item numbers change with each monthly PBS schedule. Check the PBS Schedule before prescribing from anything here.
168 entries
Moderate to severe ulcerative colitis
Not yet checked against the current source
Taken from PBS ulcerative colitis code sheet, December 2025. Nobody has checked it against the current source since. Confirm anything you prescribe from it. Applies to Australia (PBS Section 100 Highly Specialised Drugs). Open the source.
Adalimumab Humira, Amgevita, Abrilada, Hadlima, Hyrimoz, Yuflyma
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Induction (initial, change or recommencement)Online or written | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 6 (3 packs of 2) or 2 (patient under 40 kg) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 6 (3 packs of 2) or 2 (patient under 40 kg) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 6 (3 packs of 2) or 2 (patient under 40 kg) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 6 (3 packs of 2) or 2 (patient under 40 kg) | 0 | Written or online authority | |
| PBS listing | adalimumab 80mg/0.8mL syringeHumira, Yuflyma, Hyrimoz (pen only) | 3 or 1 (patient under 40 kg) | 0 | Written or online authority | |
| PBS listing | adalimumab 80mg/0.8mL penHumira, Yuflyma, Hyrimoz (pen only) | 3 or 1 (patient under 40 kg) | 0 | Written or online authority | |
| Balance, patient under 40 kg (20mg)Online or telephone | |||||
| PBS listing | adalimumab 20mg/0.2mL syringeHumira | 2 | 3 | Written or online authority | |
| PBS listing | adalimumab 20mg/0.4mL syringeAmgevita | 2 | 3 | Written or online authority | |
| PBS listing | adalimumab 20mg/0.4mL syringeAbrilada | 2 | 3 | Written or online authority | |
| Balance, patient 40 kg or more (40mg)Online or telephone | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 2 | 2 | Written or online authority | |
| First continuing and balanceOnline or telephone | |||||
| PBS listing | adalimumab 20mg/0.2mL syringeHumira | 2 (20mg/fortnight) or 4 (20mg/week) | 5 | Written or online authority | |
| PBS listing | adalimumab 20mg/0.4mL syringeAmgevita | 2 (20mg/fortnight) or 4 (20mg/week) | 5 | Written or online authority | |
| PBS listing | adalimumab 20mg/0.4mL syringeAbrilada | 2 (20mg/fortnight) or 4 (20mg/week) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | Written or online authority | |
| Subsequent continuingStreamlined authority | |||||
| PBS listing | adalimumab 20mg/0.2mL syringeHumira | 2 (20mg/fortnight) or 4 (20mg/week) | 5 | ||
| PBS listing | adalimumab 20mg/0.4mL syringeAmgevita | 2 (20mg/fortnight) or 4 (20mg/week) | 5 | ||
| PBS listing | adalimumab 20mg/0.4mL syringeAbrilada | 2 (20mg/fortnight) or 4 (20mg/week) | 5 | ||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | ||
| PBS listing | adalimumab 40mg/0.8mL penAbrilada (pen), Hyrimoz, Amgevita, Hadlima | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | ||
| PBS listing | adalimumab 40mg/0.4mL syringeHadlima, Yuflyma, Humira, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | ||
| PBS listing | adalimumab 40mg/0.4mL penHadlima, Yuflyma, Humira, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week) | 5 | ||
Golimumab Simponi
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | golimumab 100mg/mL injection, pen | 3 | 0 | Written or online authority | |
| PBS listing | golimumab 100mg/mL injection, pen | 1 | 1 | Written or online authority | |
| Continuing and balanceOnline or telephone | |||||
| PBS listing | golimumab 100mg/mL injection, pen | 1 | 5 | Written or online authority | |
Tofacitinib Xeljanz
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | tofacitinib 10mg tabs | 56 | 3 | Written or online authority | |
| PBS listing | tofacitinib 5mg tabs | 56 | 3 | Written or online authority | |
| Continuing and balanceOnline or telephone | |||||
| PBS listing | tofacitinib 10mg tabs | 56 | 5 | Written or online authority | |
| PBS listing | tofacitinib 5mg tabs | 56 | 5 | Written or online authority | |
Ozanimod Zeposia
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Dose escalation at initial or re-initiation (titration pack)Streamlined authority | |||||
| PBS listing | ozanimod 230mcg caps [4] + 460mcg caps [3] | 1 (pack) | 0 | ||
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | ozanimod 920mcg caps | 28 | 3 | Written or online authority | |
| Continuing and balanceOnline or telephone | |||||
| PBS listing | ozanimod 920mcg caps | 28 | 5 | Written or online authority | |
Upadacitinib Rinvoq
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | upadacitinib 45mg tabs | 28 | 3 | Written or online authority | |
| Continuing and balanceOnline or telephone | |||||
| PBS listing | upadacitinib 15mg tabs | 28 | 5 | Written or online authority | |
| PBS listing | upadacitinib 30mg tabs | 28 | 5 | Written or online authority | |
| Dose modificationOnline or telephone | |||||
| PBS listing | upadacitinib 15mg tabs | 28 | 1 | Written or online authority | |
| PBS listing | upadacitinib 30mg tabs | 28 | 1 | Written or online authority | |
Etrasimod Velsipity
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | etrasimod 2mg tabs | 28 | 3 | Written or online authority | |
| Continuing and balanceOnline or telephone | |||||
| PBS listing | etrasimod 2mg tabs | 28 | 5 | Written or online authority | |
Vedolizumab IV Entyvio IV
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | PUBLIC vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
| PBS listing | PRIVATE vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
| Continuing and balanceOnline or telephone | |||||
| PBS listing | PUBLIC vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
| PBS listing | PRIVATE vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
Vedolizumab subcutaneous Entyvio SC
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial treatment after 3 doses of IVOnline or written | |||||
| PBS listing | vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen | 2 | 0 | Written or online authority | |
| Initial treatment after 2 doses of IVOnline or written | |||||
| PBS listing | vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen | 2 | 2 | Written or online authority | |
| Continuing or switching to subcutaneousOnline or telephone | |||||
| PBS listing | vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen | 2 | 5 | Written or online authority | |
| Balance of supply: replacements, lost or top-upsOnline or telephone | |||||
| PBS listing | vedolizumab 108mg/0.68mL injection, 2 x 0.68mL pen | 2 | X | Written or online authority | |
Ustekinumab IV Stelara IV, Steqeyma IV
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Loading (initial, change, recommencement or balance)Online or written | |||||
| PBS listing | PUBLIC ustekinumab 130mg vial | 4 | 0 | Written or online authority | |
| PBS listing | PRIVATE ustekinumab 130mg vial | 4 | 0 | Written or online authority | |
Ustekinumab subcutaneous Stelara SC, Steqeyma SC
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| BalanceOnline or written | |||||
| PBS listing | ustekinumab 90mg syringe | 1 | 0 | Written or online authority | |
| First and subsequent continuing, and balanceOnline or telephone | |||||
| PBS listing | ustekinumab 90mg syringe | 1 | 1 (90mg/12wks) or 2 (90mg/8wks) | Written or online authority | |
| Subsequent continuing for biosimilarsStreamlined authority | |||||
| PBS listing | ustekinumab 90mg syringeSteqeyma | 1 | 1 | ||
Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| Continuing (all brands)Online or telephone | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| Continuing for biosimilarsStreamlined authority | |||||
| PBS listing | PUBLIC infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima | up to 5 | 2 | ||
| PBS listing | PRIVATE infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima | up to 5 | 2 | ||
Infliximab subcutaneous Remsima
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial or change (with 2 IV doses) or recommencement (with 1 IV dose)Online or written | |||||
| PBS listing | infliximab 120mg/mL syringe, subcutaneous | 2 | 2 | Written or online authority | |
| PBS listing | infliximab 120mg/mL pen, subcutaneous | 2 | 2 | Written or online authority | |
| Balance of supply, initialOnline or telephone | |||||
| PBS listing | infliximab 120mg/mL syringe, subcutaneous | 2 | X | Written or online authority | |
| PBS listing | infliximab 120mg/mL pen, subcutaneous | 2 | X | Written or online authority | |
| Continuing, or switching from IV to subcutaneousStreamlined authority | |||||
| PBS listing | infliximab 120mg/mL syringe, subcutaneous | 2 | 5 | ||
| PBS listing | infliximab 120mg/mL pen, subcutaneous | 2 | 5 | ||
Acute severe ulcerative colitis
Not yet checked against the current source
Taken from PBS ulcerative colitis code sheet, December 2025. Nobody has checked it against the current source since. Confirm anything you prescribe from it. Applies to Australia (PBS Section 100 Highly Specialised Drugs). Open the source.
Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| First dose as a hospital inpatient, remaining 2 doses streamlinedIncrease quantity: telephone | |||||
| PBS listing | PUBLIC infliximab 100mg vials | X* | 1 | ||
| PBS listing | PRIVATE infliximab 100mg vials | X* | 1 | ||
Adult Crohn's disease
Not yet checked against the current source
Taken from PBS Crohn's disease code sheet (adult), November 2025. Nobody has checked it against the current source since. Confirm anything you prescribe from it. Applies to Australia (PBS Section 100 Highly Specialised Drugs). Open the source.
Adalimumab Humira, Abrilada, Amgevita, Hadlima, Hyrimoz, Yuflyma
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Loading (initial, change or recommencement)Online or written | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 80mg/0.8mL syringeHumira, Yuflyma, Hyrimoz (pen only) | 3 | 0 | Written or online authority | |
| PBS listing | adalimumab 80mg/0.8mL penHumira, Yuflyma, Hyrimoz (pen only) | 3 | 0 | Written or online authority | |
| Balance (initial and continuing)Online or telephone | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 2 | 2 | Written or online authority | |
| First and subsequent continuingOnline or written | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 2 (40mg/fortnight) or 4 (40mg/week or 80mg/fortnight) | 5 | Written or online authority | |
| Subsequent continuing for biosimilarsStreamlined authority | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 5 | ||
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 5 | ||
| PBS listing | adalimumab 40mg/0.4mL syringeHadlima, Yuflyma, Hyrimoz | 2 | 5 | ||
| PBS listing | adalimumab 40mg/0.4mL penHadlima, Yuflyma, Hyrimoz | 2 | 5 | ||
Vedolizumab IV Entyvio IV
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial (doses 1, 2 and 3), change or recommencementInitial: online or written. Balance: online or telephone | |||||
| PBS listing | PUBLIC vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
| PBS listing | PRIVATE vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
| Initial (dose 4)Online or telephone | |||||
| PBS listing | PUBLIC vedolizumab 300mg vial | 1 | 0 | Written or online authority | |
| PBS listing | PRIVATE vedolizumab 300mg vial | 1 | 0 | Written or online authority | |
| ContinuingContinuing: online or written. Balance: online or telephone | |||||
| PBS listing | PUBLIC vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
| PBS listing | PRIVATE vedolizumab 300mg vial | 1 | 2 | Written or online authority | |
Vedolizumab subcutaneous Entyvio SC
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial treatment after 3 or 4 doses of IVOnline or written | |||||
| PBS listing | vedolizumab 108mg/0.68mL, 2 x 0.68mL pen | 2 | 0 | Written or online authority | |
| Initial treatment after 2 doses of IVOnline or written | |||||
| PBS listing | vedolizumab 108mg/0.68mL, 2 x 0.68mL pen | 2 | 2 | Written or online authority | |
| Continuing, or switching from IV to subcutaneousOnline or written | |||||
| PBS listing | vedolizumab 108mg/0.68mL, 2 x 0.68mL pen | 2 | 5 | Written or online authority | |
| Balance of supplyOnline or telephone | |||||
| PBS listing | vedolizumab 108mg/0.68mL, 2 x 0.68mL pen | 2 | X | Written or online authority | |
Ustekinumab IV Stelara IV, Steqeyma IV
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Loading (initial, change or recommencement)Initial: online or written. Balance: online or telephone | |||||
| PBS listing | PUBLIC ustekinumab 130mg vial | 4 | 0 | Written or online authority | |
| PBS listing | PRIVATE ustekinumab 130mg vial | 4 | 0 | Written or online authority | |
Ustekinumab subcutaneous Stelara SC, Steqeyma SC
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| BalanceOnline or telephone | |||||
| PBS listing | ustekinumab 45mg vialStelara SC | 2 | 0 | Written or online authority | |
| PBS listing | ustekinumab 45mg syringeSteqeyma SC | 2 | 0 | Written or online authority | |
| PBS listing | ustekinumab 90mg syringeSteqeyma SC | 1 | 0 | Written or online authority | |
| First and subsequent continuingContinuing: online or written. Balance: online or telephone | |||||
| PBS listing | ustekinumab 45mg vialStelara SC | 2 | 1 (90mg/12wks) or 2 (90mg/8wks) | Written or online authority | |
| PBS listing | ustekinumab 45mg syringeSteqeyma SC | 2 | 1 (90mg/12wks) or 2 (90mg/8wks) | Written or online authority | |
| PBS listing | ustekinumab 90mg syringeSteqeyma SC | 1 | 1 (90mg/12wks) or 2 (90mg/8wks) | Written or online authority | |
| Subsequent continuing for biosimilarsStreamlined authority | |||||
| PBS listing | ustekinumab 45mg syringeSteqeyma | 2 | 2 | ||
| PBS listing | ustekinumab 90mg syringeSteqeyma | 1 | 2 | ||
Upadacitinib Rinvoq
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencement, and balanceInitial: online or written. Balance: online or telephone | |||||
| PBS listing | upadacitinib 45mg tabs | 28 | 2 | Written or online authority | |
| ExtendedOnline or telephone | |||||
| PBS listing | upadacitinib 30mg tabs | 28 | 2 | Written or online authority | |
| Continuing and balanceContinuing: online or written. Balance: online or telephone | |||||
| PBS listing | upadacitinib 15mg tabs | 28 | 5 | Written or online authority | |
| PBS listing | upadacitinib 30mg tabs | 28 | 5 | Written or online authority | |
Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencementOnline or written | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| First continuingOnline or written | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| Subsequent continuingOnline or written | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| Balance of supply, all treatment phasesOnline or telephone | |||||
| PBS listing | PUBLIC infliximab 100mg vial | Written or online authority | |||
| PBS listing | PRIVATE infliximab 100mg vial | Written or online authority | |||
| Subsequent continuing for biosimilarsStreamlined authority | |||||
| PBS listing | PUBLIC infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima | up to 5 | 2 | ||
| PBS listing | PRIVATE infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima | up to 5 | 2 | ||
Infliximab subcutaneous Remsima
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial or change (with 2 IV doses) or recommencement (with 1 IV dose)Online or written | |||||
| PBS listing | infliximab 120mg/mL subcutaneous syringe | 2 | 2 | Written or online authority | |
| PBS listing | infliximab 120mg/mL subcutaneous pen | 2 | 2 | Written or online authority | |
| Balance of supply, initialOnline or telephone | |||||
| PBS listing | infliximab 120mg/mL subcutaneous syringe | 2 | up to 2 | Written or online authority | |
| PBS listing | infliximab 120mg/mL subcutaneous pen | 2 | up to 2 | Written or online authority | |
| Continuing, or switching from IV to subcutaneousStreamlined authority | |||||
| PBS listing | infliximab 120mg/mL subcutaneous syringe | 2 | 5 | ||
| PBS listing | infliximab 120mg/mL subcutaneous pen | 2 | 5 | ||
Fistulising Crohn's disease
Not yet checked against the current source
Taken from PBS fistulising Crohn's disease code sheet, November 2025. Nobody has checked it against the current source since. Confirm anything you prescribe from it. Applies to Australia (PBS Section 100 Highly Specialised Drugs). Open the source.
Adalimumab Humira, Abrilada, Amgevita, Hadlima, Hyrimoz, Yuflyma
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Loading (initial, change or recommencement)Online or written | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 6 (3 packs of 2) | 0 | Written or online authority | |
| PBS listing | adalimumab 80mg/0.8mL syringeHumira, Yuflyma, Hyrimoz (pen only) | 3 | 0 | Written or online authority | |
| PBS listing | adalimumab 80mg/0.8mL penHumira, Yuflyma, Hyrimoz (pen only) | 3 | 0 | Written or online authority | |
| BalanceOnline or telephone | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 2 | 2 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 2 | 2 | Written or online authority | |
| First and subsequent continuingContinuing: online or written. Balance: online or telephone | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 2 (40mg/fortnight, NO INC) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 2 (40mg/fortnight, NO INC) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL syringeHumira, Hadlima, Yuflyma, Hyrimoz | 2 (40mg/fortnight, NO INC) | 5 | Written or online authority | |
| PBS listing | adalimumab 40mg/0.4mL penHumira, Hadlima, Yuflyma, Hyrimoz | 2 (40mg/fortnight, NO INC) | 5 | Written or online authority | |
| Subsequent continuing for biosimilarsStreamlined authority | |||||
| PBS listing | adalimumab 40mg/0.8mL syringeAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 5 | ||
| PBS listing | adalimumab 40mg/0.8mL penAbrilada, Amgevita, Hadlima, Hyrimoz | 2 | 5 | ||
| PBS listing | adalimumab 40mg/0.4mL syringeHadlima, Yuflyma, Hyrimoz | 2 | 5 | ||
| PBS listing | adalimumab 40mg/0.4mL penHadlima, Yuflyma, Hyrimoz | 2 | 5 | ||
Ustekinumab IV Stelara IV, Steqeyma IV
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Loading (initial, change or recommencement)Initial: online or written. Balance: online or telephone | |||||
| PBS listing | PUBLIC ustekinumab 130mg vial | 4 | 0 | Written or online authority | |
| PBS listing | PRIVATE ustekinumab 130mg vial | 4 | 0 | Written or online authority | |
Ustekinumab subcutaneous Stelara SC, Steqeyma SC
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| BalanceOnline or telephone | |||||
| PBS listing | ustekinumab 90mg syringe | 1 | 0 | Written or online authority | |
| First and subsequent continuingOnline or written | |||||
| PBS listing | ustekinumab 90mg syringe | 1 | 1 (90mg/12wks) or 2 (90mg/8wks) | Written or online authority | |
| Subsequent continuing for biosimilarsStreamlined authority | |||||
| PBS listing | ustekinumab 90mg syringeSteqeyma | 1 | 1 | ||
Infliximab IV Remicade, Inflectra, Ixifi, Remsima, Renflexis
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial, change or recommencementOnline or written | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| First continuingOnline or written | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| Subsequent continuingOnline or written | |||||
| PBS listing | PUBLIC infliximab 100mg vial | X* | 2 | Written or online authority | |
| PBS listing | PRIVATE infliximab 100mg vial | X* | 2 | Written or online authority | |
| Balance, all phasesOnline or telephone | |||||
| PBS listing | PUBLIC infliximab 100mg vial | Written or online authority | |||
| PBS listing | PRIVATE infliximab 100mg vial | Written or online authority | |||
| Subsequent continuing for biosimilarsStreamlined authority | |||||
| PBS listing | PUBLIC infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima | up to 5 | 2 | ||
| PBS listing | PRIVATE infliximab 100mg vialInflectra, Renflexis, Ixifi, Remsima | up to 5 | 2 | ||
Infliximab subcutaneous Remsima
| Item | Formulation | Qty | Rpts | Streamlined code | Copy |
|---|---|---|---|---|---|
| Initial or change (with 2 IV doses) or recommencement (with 1 IV dose)Online or written | |||||
| PBS listing | infliximab 120mg/mL syringe, subcutaneous | 2 | 2 | Written or online authority | |
| PBS listing | infliximab 120mg/mL pen, subcutaneous | 2 | 2 | Written or online authority | |
| Balance of supply, including switching formulationOnline or telephone | |||||
| PBS listing | infliximab 120mg/mL syringe, subcutaneous | 2 | up to 2 | Written or online authority | |
| PBS listing | infliximab 120mg/mL pen, subcutaneous | 2 | up to 2 | Written or online authority | |
| Continuing, or switching from IV to subcutaneousStreamlined authority | |||||
| PBS listing | infliximab 120mg/mL syringe, subcutaneous | 2 | 5 | ||
| PBS listing | infliximab 120mg/mL pen, subcutaneous | 2 | 5 | ||
No item numbers match your search.
Notes
- X: the maximum quantity or number of repeats is specified within the restriction criteria.
- For streamlined authority items, approval must be sought from Services Australia for quantities or repeats greater than the listed values, if permitted.
- PUBLIC and PRIVATE refer to the hospital setting in which the infusion is supplied.